UCLA researchers have created a deep learning-enhanced chemiluminescence vertical flow assay (CL-VFA) for cardiac troponin I testing. This innovative platform allows for portable, cost-effective testing that meets clinical standards for detecting heart attacks. The technology aims to improve access to rapid cardiac diagnostics, especially in resource-limited settings.
The new point-of-care sensor can deliver results in just 25 minutes, significantly aiding clinical decision-making. With a price point of approximately $222 for the reader and $4 per test, this solution is designed to be affordable and accessible. The integration of AI-driven analysis with high-sensitivity biosensing marks a significant advancement in cardiac care.
• AI-driven analysis enhances the accuracy of cardiac diagnostics.
• Portable testing technology democratizes access to cardiac care.
Deep learning algorithms process images to determine cardiac troponin I concentrations.
Chemiluminescence is used to generate light signals for detecting troponin levels.
Point-of-care testing allows for immediate cardiac diagnostics outside traditional labs.
UCLA is at the forefront of developing AI technologies for healthcare diagnostics.
Medical Xpress on MSN.com 6month
thecardiologyadvisor.com 10month
The Nation Newspaper on MSN.com 6month
Isomorphic Labs, the AI drug discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital for the first time. The $600
How to level up your teaching with AI. Discover how to use clones and GPTs in your classroom—personalized AI teaching is the future.
Trump's Third Term? AI already knows how this can be done. A study shows how OpenAI, Grok, DeepSeek & Google outline ways to dismantle U.S. democracy.
Sam Altman today revealed that OpenAI will release an open weight artificial intelligence model in the coming months. "We are excited to release a powerful new open-weight language model with reasoning in the coming months," Altman wrote on X.